Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?

被引：1
|
作者：
Rizzo, Alessandro [1 ]
Palmiotti, Gennaro [1 ]
机构：
[1] IRCCS Ist Tumori Giovanni Paolo II, Struttura Semplice Dipartimentale Oncol Med, Presa Carico Globale Paziente Oncol Don Toni, Viale Orazio Flacco 65, I-70124 Bari, Italy
来源：
IMMUNOTHERAPY | 2022年 / 14卷 / 10期
关键词：
atezolizumab; breast cancer; immune checkpoint inhibitors; immunotherapy; pembrolizumab; triple-negative breast cancer; IMMUNOTHERAPY;
D O I：
10.2217/imt-2022-0021
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：755 / 758
页数：4
相关论文
共 50 条
  • [21] De-escalating treatment with neoadjuvant chemotherapy in early triple-negative breast cancer
    Murillo, Serafin Morales
    Cudos, Ariadna Gasol
    Der-Abrain, Noemi Tuset
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer
    Moore-Smith, Lakisha
    Forero-Torres, Andres
    Stringer-Reasor, Erica
    SURGICAL CLINICS OF NORTH AMERICA, 2018, 98 (04) : 773 - +
  • [23] Triple-negative breast cancer: Neoadjuvant durvalumab improves prognosis
    Kunzell, Judith Lorenz
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (02)
  • [24] Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
    Denkert, Carsten
    Schneeweiss, Andreas
    Rey, Julia
    Karn, Thomas
    Hattesohl, Akira
    Weber, Karsten E.
    Rachakonda, Sivaramakrishna
    Braun, Michael
    Huober, Jens
    Jank, Paul
    Sinn, Hans-Peter
    Zahm, Dirk-Michael
    Felder, Barbel
    Hanusch, Claus
    Teply-Szymanski, Julia
    Marme, Frederik
    Fehm, Tanja
    Thomalla, Jorg
    V. Sinn, Bruno
    Stiewe, Thorsten
    Marczyk, Michal
    Blohmer, Jens-Uwe
    van Mackelenbergh, Marion
    Schem, Christian
    Staib, Peter
    Link, Theresa
    Muller, Volkmar
    Stickeler, Elmar
    Stover, Daniel G.
    Solbach, Christine
    Metzger-Filho, Otto
    Jackisch, Christian
    Geyer Jr, Charles E.
    Fasching, Peter A.
    Pusztai, Lajos
    Nekljudova, Valentina
    Untch, Michael
    Loibl, Sibylle
    CELL REPORTS MEDICINE, 2024, 5 (11)
  • [25] Controversial issues in the neoadjuvant treatment of triple-negative breast cancer
    Fitzpatrick, Amanda
    Tutt, Andrew
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [26] Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast Cancer
    Stover, Daniel G.
    Bell, Caitlin F.
    Tolaney, Sara M.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (03) : 6 - 12
  • [27] Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
    Amos, Keith D.
    Adamo, Barbara
    Anders, Carey K.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012
  • [28] Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy
    Marra, Antonio
    Curigliano, Giuseppe
    CANCER JOURNAL, 2021, 27 (01): : 41 - 49
  • [29] Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer
    Davis, Andrew A.
    Gradishar, William J.
    ONCOLOGY-NEW YORK, 2020, 34 (05): : 176 - +
  • [30] Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancer
    Wei, Yuhan
    Li, Qiao
    Mo, Hongnan
    Qi, Yalong
    Ge, Hewei
    Sun, Xiaoying
    Fan, Ying
    Zhang, Pin
    Wang, Jiayu
    Luo, Yang
    Wang, Jing
    Ma, Fei
    TRANSLATIONAL ONCOLOGY, 2025, 51
12345